Gilead prices coronavirus drug at $2,340 for rich countries

The maker of a drug shown to shorten recovery time for severely ill COVID-19 patients says it will charge $2,340 for a typical treatment course for people covered by government health programs in the United States and other developed countries.

The maker of a drug shown to shorten recovery time for severely ill COVID-19 patients says it will charge $2,340 for a typical treatment course for people covered by government health programs in the United States and other developed countries. Gilead Sciences announced the price Monday for remdesivir, and said the price would be $3,120 for patients with private insurance. The amount that patients pay out of pocket depends on insurance, income and other factors.

"We're in uncharted territory with pricing a new medicine, a novel medicine, in a pandemic," Gilead's chief executive, Dan O'Day, told The Associated Press. "We believe that we had to really deviate from the normal circumstances" and price the drug to ensure wide access rather than based solely on value to patients, he said.

The 250,000 treatment courses that the company had donated to the US and other countries will run out in about a week, and the prices will apply to the drug after that. In the US, federal health officials have allocated the limited supply to states, but that will end in September.

"We should have sufficient supply ... but we have to make sure it's in the right place at the right time," O'Day said In 127 poor or middle-income countries, Gilead is allowing generic makers to supply the drug; two countries are doing that for around $600 per treatment course. Remdesivir's price has been highly anticipated since it became the first medicine to show benefit in the pandemic, which has killed more than half a million people globally in six months.

The drug interferes with the coronavirus's ability to copy its genetic material. In a US government-led study, remdesivir shortened recovery time by 31% — 11 days on average versus 15 days for those given just usual care. It had not improved survival according to preliminary results after two weeks of followup; results after four weeks are expected soon. The Institute for Clinical and Economic Review, a nonprofit group that analyzes drug prices, said remdesivir would be cost-effective in a range of $4,580 to $5,080 if it saved lives. But recent news that a cheap steroid called dexamethasone improves survival means remdesivir should be priced between $2,520 and $2,800.

The drug is has emergency use authorization in the U.S. and Gilead has applied for full approval.(AP) RUP RUP.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)